Enliven Therapeutics Strengthens Leadership with New Board Member Scott Garland
Enliven Therapeutics, Inc. (Nasdaq: ELVN) has announced the appointment of biopharma veteran Scott Garland to its Board of Directors, a strategic move that coincides with the company's preparations for a pivotal Phase 3 trial of its leading candidate, ELVN-001.
Key Leadership Changes at Enliven
Enliven Therapeutics, a clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutics, has appointed Scott Garland to its Board of Directors. This decision follows the announcement that Andrew Phillips, Ph.D., will resign from his position effective January 7, 2026. The transition reflects Enliven's shift towards late-stage development and commercialization activities.
- Appointment of Scott Garland: A seasoned executive with over 30 years in the biopharmaceutical industry.
- Resignation of Andrew Phillips, Ph.D.: Stepping down to facilitate the Board's evolution.
- Upcoming Phase 3 Trial: Enliven is set to initiate a pivotal trial for ELVN-001 in patients with chronic myeloid leukemia (CML) in 2026.
The Expertise of Scott Garland
Mr. Garland's extensive experience in oncology and hematology commercialization positions him as a valuable asset to Enliven as it heads into its next development phase. Rick Fair, CEO of Enliven, emphasized that Garland's proven track record will aid in scaling operations and guiding commercial teams to ensure the successful launch of ELVN-001.
"Scott brings vast experience spanning oncology and hematology commercialization at both big pharma and early commercial-stage biopharmaceutical companies," said Rick Fair.
Prior to this role, Garland held executive positions at various companies including:
- Chief Executive Officer at PACT Pharma, Inc.
- President and Chief Executive Officer at Portola Pharmaceuticals, driving its acquisition by Alexion Pharmaceuticals.
- Chief Commercial Officer at Relypsa, Inc. and Exelixis, Inc.
Shift Towards Late-Stage Development
As Enliven prepares for the upcoming Phase 3 trial of ELVN-001, the company reflects on the achievements made under Dr. Phillips's leadership. Rich Heyman, the Chairman of the Board, acknowledged Phillips's invaluable contributions during this critical growth period.
"Andy's scientific insight has been instrumental as we advanced ELVN-001 into the clinic," remarked Rich Heyman.
Dr. Phillips expressed pride in the team’s progress and is hopeful about the company's future, noting the timely transition as Enliven shifts focus.
Looking Ahead: The Future of ELVN-001
Following promising clinical data for ELVN-001 reported in 2025, Enliven's trajectory is aimed at not only initiating the Phase 3 trial but also laying groundwork for potential commercialization. Recent leadership enhancements, including the appointment of Rick Fair and Scott Garland, highlight the company's commitment to experienced governance during this pivotal transition.
About Enliven Therapeutics
Enliven is committed to advancing clinical-stage biopharmaceuticals, focusing on small molecule therapies that improve patient outcomes. With aspirations to meet unmet medical needs via precision oncology, the company operates from Boulder, Colorado.
Forward-Looking Statements
This article contains forward-looking statements related to Enliven Therapeutics and its future performance regarding the commercialization of ELVN-001. These predictions encompass financial goals and potential outcomes of clinical trials which are subject to risks and uncertainties.